<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03553758</url>
  </required_header>
  <id_info>
    <org_study_id>2018P000417</org_study_id>
    <nct_id>NCT03553758</nct_id>
  </id_info>
  <brief_title>EEG Studies of Ketamine General Anesthesia</brief_title>
  <official_title>Electroencephalogram Studies of Induction and Recovery From Ketamine-Induced General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this research study to find out how and where ketamine acts in the brain.
      Ketamine is an anesthetic (a drug or agent used to decrease or eliminate the feeling of pain
      by putting you in an unconscious state). We will look at the brain using a machine that
      records the brain's electrical activity, called an electroencephalogram (EEG).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, participants will be given ketamine at a high enough dosage to induce general
      anesthesia. EEG recording will be conducted during this time. Cognitive assessments, computer
      tasks and pain monitoring will be administered.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EEG power at ketamine-included loss of responsiveness</measure>
    <time_frame>Approximately 60 minutes</time_frame>
    <description>EEG power examined at ketamine-included loss of responsiveness</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ketamine EEG Dynamics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EEG recordings will be obtained from 15 subjects undergoing ketamine general anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximatel 60 minutes.</description>
    <arm_group_label>Ketamine EEG Dynamics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18 to 45

          -  Normal body weight and habitus, BMI less than or equal to 30

          -  Non-smoker

          -  American Society of Anesthesiologists (ASA) physical status classification P1

        Exclusion Criteria:

          -  Cardiovascular: myocardial infarction, coronary artery disease, peripheral vascular
             disease, arrhythmia, congestive heart failure, valvular disease, hypertension

          -  Respiratory: bronchitis, chronic obstructive pulmonary disease, smoking, shortness of
             breath

          -  Hepatic: hepatitis, jaundice, ascites

          -  Neurologic: seizure, stroke, positive neurologic findings on neurologic examination,
             multiple sclerosis, Meniere's disease, Parkinson's disease, neuropathy, peripheral
             stenosis

          -  Gastrointestinal: esophageal reflux, hiatal hernia, ulcer

          -  Endocrine: diabetes, thyroid disease

          -  Renal: acute or chronic severe renal insufficiency

          -  Hematologic: blood dyscrasias, anemia, coagulopathies, on anticoagulant therapy

          -  Musculoskeletal: prior surgery or trauma to head neck or face, arthritis, personal or
             family history of malignant hyperthermia

          -  Psychiatric: history or treatment for an active psychiatric problem, depression

          -  Reproductive: pregnancy, breast-feeding

          -  Medications: regular use of prescription and non-prescription medications expected to
             affect CNS function, St. John's Wort

          -  Allergies: labetalol, ondansetron, glycopyrrolate, ketamine, midazolam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2018</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Oluwaseun Johnson-Akeju, MD, MMSc</investigator_full_name>
    <investigator_title>Associate Professor of Anaesthesia</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 9, 2020</submitted>
    <returned>July 23, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

